Aladdin® Reducing Agents
A reducing agent, also known as a reductant, is a substance that has the ability to donate electrons to another substance.
Knowledge Base
Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides
1,700+ technical articles by Aladdin Scientific's scientists on reagent selection, reaction mechanisms, assay design and formulation. New every week.
5929 articles
Immunocytochemistry (ICC) protocol
Immunocytochemistry (ICC) protocol
CC-92480,Dalcetrapib,Tovorafenib and AZD4604
The targets of action of drugs involve receptors, enzymes, ion channels, transporters, immune system, genes and many others. This paper describes four drugs involving enzyme targets of action and their synthetic routes.
GDC-1971: SHP2 Inhibitor Ushering in a New Era of Cancer Treatment
In recent years, protein tyrosine phosphatase SHP2 has become a highly regarded research target in the field of oncology in mediating the RAS-driven MAPK signaling pathway. Its treatment methods are not limited to single drug use, but also can work together with KRAS inhibitors, showing good ...
ROS1 Fusion Inhibitor NVL-520 with MGAT2 Inhibitor BMS-963272
ROS1 Fusion Inhibitor NVL-520 with MGAT2 Inhibitor BMS-963272
The process path of EBL-3183: from indole to preclinical inhibitor
Metallo-β-lactamases (MBLs) are regarded as major determinants of carbapenem antibiotic resistance. Therefore, the search for new MBL inhibitors has become an urgent task at present. Recently, Prof. Andrei Baran and his team published an article in Org. Process Res. Dev, detailing the synthetic ...
Explore the Industrialization Process of SOS1 Inhibitor MRTX0902
MRTX0902 is a highly effective SOS1:KRAS complex inhibitor that exhibits excellent brain penetration, high oral bioavailability, and strong selectivity. When combined with MRTX849 (1,2)-adagrasib (KRAZATI), it can significantly enhance its anti-tumor activity.
Targeted drug discovery: scarce and inefficient, what is the geometry of its effectiveness?
Although target-based drug discovery is currently the dominant approach to drug discovery and development, the latest comprehensive assessment shows that its results are not as good as they could be. The number of drugs discovered by this approach is relatively small, and their therapeutic ...
Action type of ligand acting on target
Action type of ligand acting on target